These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29678300)

  • 1. In vitro activity of oritavancin against planktonic and biofilm states of vancomycin-susceptible and vancomycin-resistant enterococci.
    Yan Q; Karau MJ; Patel R
    Diagn Microbiol Infect Dis; 2018 Aug; 91(4):348-350. PubMed ID: 29678300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.
    Wu T; Meyer K; Harrington AT; Danziger LH; Wenzler E
    J Antimicrob Chemother; 2019 May; 74(5):1300-1305. PubMed ID: 30753495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci.
    Neudorfer K; Schmidt-Malan SM; Patel R
    Diagn Microbiol Infect Dis; 2018 Jan; 90(1):58-63. PubMed ID: 29195766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an
    Belley A; Arhin FF; Moeck G
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of oritavancin alone and in combination against vancomycin-susceptible and -resistant enterococci in an in-vivo Galleria mellonella survival model.
    Meyer KA; Deraedt MF; Harrington AT; Danziger LH; Wenzler E
    Int J Antimicrob Agents; 2019 Aug; 54(2):197-201. PubMed ID: 31034937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New semisynthetic teicoplanin derivatives have comparable in vitro activity to that of oritavancin against clinical isolates of VRE.
    Szűcs Z; Ostorházi E; Kicsák M; Nagy L; Borbás A; Herczegh P
    J Antibiot (Tokyo); 2019 Jul; 72(7):524-534. PubMed ID: 30874609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of oritavancin and nisin alone and their combination against vancomycin resistant enterococci strains in hospitalized patients in Turkiye.
    Sefali S; Y N
    Indian J Med Microbiol; 2024; 47():100489. PubMed ID: 37890415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.
    Arias CA; Mendes RE; Stilwell MG; Jones RN; Murray BE
    Clin Infect Dis; 2012 Apr; 54 Suppl 3(Suppl 3):S233-8. PubMed ID: 22431854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019).
    Carvalhaes CG; Sader HS; Streit JM; Castanheira M; Mendes RE
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0166721. PubMed ID: 34807761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin.
    Dahesh S; Wong B; Nizet V; Sakoulas G; Tran TT; Aitken SL
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31235559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents.
    Mendes RE; Castanheira M; Farrell DJ; Flamm RK; Sader HS; Jones RN
    J Glob Antimicrob Resist; 2017 Mar; 8():28-32. PubMed ID: 27939809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agar dilution minimum inhibitory concentrations under-represent oritavancin in vitro activity against staphylococci and enterococci.
    Arhin FF; Moeck G
    J Glob Antimicrob Resist; 2017 Jun; 9():85-86. PubMed ID: 28455075
    [No Abstract]   [Full Text] [Related]  

  • 15. Eradication of Vancomycin-Resistant Enterococci by Combining Phage and Vancomycin.
    Shlezinger M; Coppenhagen-Glazer S; Gelman D; Beyth N; Hazan R
    Viruses; 2019 Oct; 11(10):. PubMed ID: 31623253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro Antimicrobial Activity of Fosfomycin, Rifampin, Vancomycin, Daptomycin Alone and in Combination Against Vancomycin-Resistant
    Tong J; Jiang Y; Xu H; Jin X; Zhang L; Ying S; Yu W; Qiu Y
    Drug Des Devel Ther; 2021; 15():3049-3055. PubMed ID: 34285472
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Brown Gandt A; Griffith EC; Lister IM; Billings LL; Han A; Tangallapally R; Zhao Y; Singh AP; Lee RE; LaFleur MD
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
    Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci.
    Arhin FF; Seguin DL; Belley A; Moeck G
    Diagn Microbiol Infect Dis; 2017 Oct; 89(2):168-171. PubMed ID: 28733126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an
    Jahanbakhsh S; Singh NB; Yim J; Kebriaei R; Smith JR; Lev K; Tran TT; Rose WE; Arias CA; Rybak MJ
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094136
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.